Chronic eosinophilic leukaemia (CEL): a distinct myeloproliferative disease

Rudolf Weide, K. Havemann(Philipps University of Marburg), Christian Görg, Yasemien Mehraein(Philipps University of Marburg), Ulrich Kaiser(University of Applied Sciences Landshut), Harald Rieder(Philipps University of Marburg), M. Wolf(Klinikum Kassel), Ulf Seifart

British Journal of Haematology

January 1, 1997

10.1046/j.1365-2141.1997.d01-1991.x

Cited by 35

Related Papers

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

|The Lancet|2013|1.5k

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

|The Lancet Oncology|2015|402

Incidence and risk factors of central nervous system recurrence in aggressive lymphoma—a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)

|Annals of Oncology|2006|280

<i>CEBPA</i> mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome

|Blood|2021|170

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

|Blood|2009|157